U.S. FDA to review data on Vytorin cancer risk
WASHINGTON, Aug 21 (Reuters) - U.S. Food and Drug Administration officials plan to review recently publicized data that showed a higher rate of cancer in patients taking Merck & Co Inc (MRK.N) and Schering-Plough Corp's (SGP.N) cholesterol drug Vytorin.
The agency, in a notice posted on its website on Thursday, said it will take about three months before it receives final results from the so-called SEAS study. It will likely take another six months for the FDA to complete its review and draw any conclusions, it added. (Reporting by Susan Heavey; Editing by Tim Dobbyn)
© Thomson Reuters 2009 All rights reserved
Green Shoots / Brown Weeds
Jobless claims drop steeply
The number of U.S. workers filing new claims for jobless benefits fell sharply last week, although the data was distorted by an unusual pattern of layoffs in the automotive industry. Full Article
Bad weather hurts retail sales
Sales fell at many U.S. apparel retailers and warehouse club stores in June as the weak economy and cool, rainy weather dashed interest in summer shopping for consumers across the country. Full Article
